Drug Approval | July 11, 2023
NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData
Approval to dramatically change CAR-T therapies landscape
Approval to dramatically change CAR-T therapies landscape
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
This product will be manufactured at Lupin's Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
